T he identification and characterization of specific receptors for a wide variety of biologic molecules have provided insights into cellular biology.
T he identification and characterization of specific receptors for a wide variety of biologic molecules have provided insights into cellular biology. 1 Transport of hydrophobic lipids was first shown to be mediated by specific membranes receptors for the low density lipoproteins (LDL). 2 In this process LDL binds to its receptor, the LDL-receptor complex is internalized, and the LDL is delivered to lysosomes where cholesteryl ester hydrolysis releases free cholesterol for cellular metabolism. The LDL surface receptor number is regulated to provide the cell with the optimal amount of exogenously supplied cholesterol. 2 A number of separate defects in this LDL receptor pathway lead to the development of familial hypercholesterolemia, a disease characterized by decreased delivery of cholesterol to cells via the LDL receptor pathway, increased plasma LDL cholesterol concentrations, and accelerated atherosclerosis. 34 The study of lipoprotein-receptor interactions has led to insights into cellular cholesterol metabolism and normal and abnormal lipoprotein metabolism.
Studies of the LDL receptor have stimulated investigation into other cellular receptors that would recognize apolipoproteins (apo) other than the apo B of LDL. Of particular interest are receptors specifically recognizing the apolipoprotein in high density lipoproteins (HDL). While LDL has been assigned the lipid delivery role, it has been proposed that HDL facilitates the removal of cholesterol from cells. 5 Previous studies with skin fibroblasts indicated that HDL was not metabolized by the LDL receptor pathway.^1 2 In addition, a high affinity fibroblast receptor that is upregulated by cholesterol loading has recently been identified in human fibroblasts and cultured arterial smooth muscle cells. Therefore, unique, saturable HDL receptors that may have a role in reverse cholesterol transport have been identified in peripheral cells. 10 " 12 Since the liver plays a central role in lipid and lipoprotein metabolism, receptors identified in peripheral cells have been sought in the liver. Specific membrane-bound hepatic receptors for apo B and apo E have been identified in a number of mammals including man. 13 " 20 Specific binding for HDL, independent of apo E, has also been evaluated. If HDL were to facilitate cholesterol removal from the body, hepatic delivery of cholesterol from peripheral cells to the liver might be receptor-mediated. In animal models, radiolabeled HDL is cleared by the liver 21 " 23 and metabolized by both parenchymal and nonparenchymal liver cells. 24 " 28 However, the HDL metabolism in these animal models is not specific for HDL. Lipoprotein particles containing apo B or apo E competed for HDL binding in studies conducted in rats 2< x swine, 27 and rabbits. 28 Therefore, the significance of HDL binding to liver has been clouded by the apparent lack of binding site specificity.
We evaluated the characteristics of HDL binding to human hepatic membranes by using HDL isolated from a patient who had no circulating apo E. 29 These studies indicate that human liver contains a specific, saturable, calcium-independent receptor for HDL that is unique and distinct from the hepatic LDL receptor.
Methods

Liver Membrane Preparation
Biopsy specimens of human liver from normal and familial hypercholesterolemic subjects were obtained intraoperatively after informed consent had been given. Use of intraoperative hepatic biopsies for research purposes was approved by the Human Experimentations Committee at the University of Pittsburgh. Tissue was placed immediately in a beaker and all processing occurred at 4°C in a manner similar to that described previously. 19 After the tissue was minced with a razor blade, it was washed with an ice-cold buffer containing 150 mM NaCI, 1 mM EDTA, and 10 mM Tris-HCI (pH 8.0). Homogenization was performed by six strokes of a motor-driven Teflon pestle in a buffer containing 0.25 M sucrose, 1 mM EDTA, and 10 mM Tris-HCI (pH 8.0). The homogenized preparations (10 mg/ml) were centrifuged for 10 minutes at 1000 g. The supernatant solution was recentrifuged for 25 minutes at 10,000 g, followed by ultracentrifugation at 100,000 g for 60 minutes. The pellet from this ultracentrifugation was resuspended in a buffer containing 150 mM NaCI and 10 mM Tris-HCI (pH 8.0) and flushed 10 times through a 22-gauge needle. These membranes were recentrifuged 15 minutes at 100,000 g, and the membrane pellets were then frozen in dry ice and stored in liquid nitrogen until they were used in the binding assays.
Lipoprotein Preparation
HDL3 (d = 1.125-1.210 g/ml) and LDL (d = 1.030-1.050 g/ml) were prepared from 500 ml of plasma collected in 0.1% EDTA by plasmapheresis after a 12-to 14-hour fast. HDLg was isolated from a subject lacking plasma apolipoprotein E in the plasma. 29 Lipoproteins were separated by preparative ultracentrifugation at 4° C (24 hours for LDL and 48 hours for HDL3) 30 by using KBr for density gradient adjustment. 31 After centrifugation, subfractions were dialyzed at 4° C against 150 to 250 volumes of phosphate-buffered saline (pH 7.0, GIBCO, Grand Island, New York). Each isolated lipoprotein fraction was sterilized by 0.45 pm filtration (Millipore Corporation, Bedford, Massachusetts) and used within 2 weeks of preparation. Apo A-l was isolated from HDL (d = 1.063-1.21 g/ml) from normal volunteers. After chloroform/methanol (2:1, vol/vol) delipidation, apo A-l was purified by gel filtration on Sephadex G-200 in 8 M urea as reported previously. 32 Each preparation was a single band on 7.5% NaDodSO 4 polyacrylamide gel electrophoresis. Apo A-l was iodinated by the iodine monochloride method 33 and a modification of the technique described for lipoproteins. 34 A 60% to 80% efficiency of iodination was achieved and ~0.5 mol of iodine was incorporated per mole of apo A-l. The iodinated apo A-l preparation used for binding assays was free of incompetent (nonself-associating) monomer as evaluated by nigh-per-formance liquid chromatography. 35 The 125 Iapo A-l was incubated with apo E-free HDL3 for 30 minutes in a 37° C shaker bath. 125 l-apo A-l associated with HDL3 ( I25 l-apo A-l HDL) was separated from free 125 l-apo A-l by a 36-hour, 4° C, 140,000 g ultracentrifugation at a 1.21 g/ml density in a 40.3 Beckman rotor (Beckman, Fullerton, California). From 86% to 94% of the radiolabeled apo A-l remained associated with the HDL. After a 4° C, 16-to 25-hour dialysis against 300 to 500 volumes of phosphatebuffered saline to remove KBr and after Millipore filtration, the protein concentration was determined by the method of Lowry 36 with use of ovalbumin as standard. Specific activities for the 125 l-apo A-l HDL were 2.7 to 3.6 x 10 8 Bequerels/mg HDL protein.
Aliquots of HDL underwent arginine modification as described for lipoproteins. 37 Acetoacetylation was performed utilizing the diketene reagent as reported by Mahley and co-workers. 38 Charge modification of the HDL was confirmed by agarose gel electrophoresis. Modification of tyrosine residues in HDL was performed by nitration of either radiolabeled or unlabeled HDL by a method developed by Eliot Brinton and co-workers based on previously described methods. 39 Tetranitromethane (TNM) (Aldrich Chemical Company, Incorporated, Milwaukee, Wisconsin) was dissolved in 95% ethanoi and added to HDL, (1 mg protein/ml) in a 0.15 M NaCI, 5 mM EDTA, pH 7.4 buffer at a final TNM concentration of 0.3 mM. Samples were incubated at 25° C for 5 minutes, and the HDL was extensively dialyzed against a 0.15 M NaCI, 5 mM EDTA at 4° C overnight.
Binding of 125 l-Apo A-l HDL to Liver Membranes
Frozen liver membrane preparations were thawed and resuspended through a 22-gauge needle in a 50 mM NaCI, 30 mM Tris-HCI (pH 7.5) buffer and adjusted to a membrane protein concentration of 10-12 mg/ml. Membranes were then sonicated by five 4-second pulses at the 55 W-setting with an ultrasonics microtip (Heat Systems Ultrasonics, Incorporated, Plainview, New York). Preliminary experiments demonstrated that 125 l-apo A-l HDL binding to hepatic membranes was linear from 50 /xg to 200 /^tg hepatic membrane protein per assay. Membrane pellets were suspended in a buffer containing 25 mM NaCI and 50 mM Tris-HCI (pH 7.5), for a final membrane protein concentration of 5 to 10 mg/ml. From 10 to 25 fxg of this membrane suspension was then added to the assay, which resulted in a final assay buffer containing 50 mM NaCI, 20 mM Tris-HCI (pH 7.5), and either 1 mM CaCI 2 or 30 mM EDTA. 125 l-apo A-l HDL was added at the concentrations indicated in the respective tables and figure legends with or without unlabeled HDL to a total assay mixture volume of 0.1 ml. Incubations were carried out at 0° Cor 37° C for the indicated time period. Bound 125 l-apo A-l HDL was separated from free ligand by a 30-minute, 100,000 g centrif ugation of 50 ix\ of the assay mixture through 125 /xl phosphate-buffered saline (PBS) in a 30° angle rotor by an air-driven ultracentrifuge (Beckman, Palo Alto, California). The supernatant was removed from the pellets by vacuum aspiration, and the pellet was washed once with 125 ^\ of PBS. The cellulose nitrate tube tips containing the membrane pellet were sliced and the radioactivity in the pellet was quantified in a Biogamma II scintillation counter (Beckman, Palo Alto, California). Specifically bound 125 |-apo A-l HDL was defined as the difference in 125 Iapo A-l HDL bound in samples that were incubated with and without unlabeled HDL. Competition binding experiments were performed by the addition of the indicated concentrations of unlabeled ligand (LDL, HDL, asialofetuin, and chemically modified HDL) anti-apo A-l, anti-apo A-ll, and anti-apo B with the indicated concentrations of radiolabeled HDL. After a 2-hour, 37° C incubation, the bound and free 125 l-apo A-l HDL were separated and quantitated as described above.
Data Analysis of Membrane Binding Assays
Binding data were analyzed by using MLAB, an on-line computer modeling program developed at the National Institutes of Health. This system permits the fitting of experimental data to theoretical functions by the Marquardt-Levenberg curve-fitting method. Variable parameters in the theoretical function are adjusted by iteration so as to minimize the sum of the squares of the differences between experimental and theoretical data. Primary data were analyzed directly, rather than as linear transformations as described by Scatchard, 40 where SBL corresponds to specifically bound ligand, FL to free ligand, R to the number of receptor sites per assay, KD to the equilibrium dissociation constant, and the subscripts 1 and 2 correspond to the first and second sites respectively.
Specifically bound ligand was computed according to the following equation:
where T is the total cpm bound, C is the cpm bound in the presence of excess cold ligand (XS), L is the labeled ligand concentration, and B is the membrane-free blank.
Cellular Metabolism Studies
The regulation of hepatic HDLg metabolism was assessed by using the well-differentiated human hepatoma cell line, HEPG2.
41 From 2 to 4 x 10 5 cells were plated in 2 cm 2 wells (Costar, Cambridge, Massachusetts) on Day 1 in RPM1 1640 medium containing 10% fetal calf serum, penicillin, and streptomycin. On Day 3, the medium was replaced by a totally defined serum-free medium, 42 which did or did not contain 50 ng cholesterol/ml. The cholesterol was added to the culture medium after it had been dissolved in ethanol (5 mg/ml) as previously outlined." After a 24-hour incubation in either the cholesterol-free, serum-free medium or in medium containing 50 fig cholesterol/ml, the medium was changed to include the concentrations of 125 l-apo A-l HDL indicated in the figure legend in either the absence or the presence of 10-fold excess unlabeled HDL,. After a 2-hour, 37° C incubation with the radiolabeled HDL, the medium was removed and the cells were washed six times with ice-cold phosphate-buffered saline (pH 7.0). The cells were solubilized with 0.5 ml of 1 N NaOH. The eel I-associated radioactivity was quantitated and the cellular protein content was determined by the method of Lowry. than the binding observed in the presence of 1 mM calcium and more than 90% of the specific binding at saturation was EDTA-resistant. However, as observed previously with LDL binding, the incubation at 37° C resulted in a nearly twofold increase in the binding of radiolabeled HDL. 19 Therefore, the binding of 125 l-apo A-l HDL to human hepatic membranes was sensitive to the incubation temperature, reached equilibrium by 2 hours, and was EDTA-resistant.
The effect of HDL concentration on specific HDLhepatic membrane binding was also evaluated at both 0° and 37° C (Figure 2 ). Increasing ligand concentration resulted in increased HDL binding at both incubation temperatures. In addition, the binding reached saturation at both temperatures. The primary data were analyzed directly by using the equations given in the Methods section, and receptor number and affinity are given in Table 1 . If we assume a single receptor model, the affinity of the HDL-membrane interaction was increased twofold by changing the incubation temperature from 0° to 37° C. Fitting these data to a two-receptor model provided no additional information. Therefore, l2S l-apo A-l HDL binding to hepatic membranes is saturable and can be accounted for by a single receptor site in which affin- The receptor number and affinity were calculated by using the specific binding data as described in Methods and by assuming either a single-or a two-receptor site model. Values represent means + SE. ity, but not receptor number, are affected by the incubation temperature.
The specificity of the HDL-hepatic membrane interaction was assessed with competition binding assays. Increasing concentrations of HDL, asialofetuin, and LDL, ligands known to interact with specific hepatic receptors, were incubated with the hepatic membranes in the presence of 50 /^g/rnl 125 l-apo A-l HDL at both 0° and 37° C (Figure 3) . Unlabeled HDL competed effectively with the radiolabeled ligand; however, LDL and asialofetuin were unable to decrease the binding of 125 l-apo A-l HDL binding.
Chemical modification of lysine and arginine residues prevents LDL from interacting with its receptor. 37 - 38 The lysine and arginine residues in HDL were modified and the ability of these preparations to inhibit The inability of nitrated HDL to compete with radiolabeled HDL was paralleled by the reduced level of direct binding observed with radiolabeled HDL that had undergone nitration (Table 2) . However, nitration did not alter the specific activity of the radiolabeled HDL. In addition, no significant apoprotein aggregation was generated as determined by autoradiography of sodium dodecyl sulfate gel electrophoresis of the nitrated tively bound nitrated 125 I-HDL were only 40% and 32% that of unmodified HDL. Therefore nitration, which modifies tyrosine residues, alters HDL binding to hepatic membranes.
Finally, the apolipoprotein specificity for the HDLmembrane interaction was assessed immunologically (Table 3) . Both LDL and anti-apo B antibodies were ineffective in reducing the HDL-membrane binding. In contrast, anti-apo A-l, anti-apo A-ll, and unlabeled HDL reduced binding by 60% or more. Therefore, the binding of 125 l-apo A-l HDL to human hepatic membranes demonstrated a unique specificity.
Individuals homozygous for familial hypercholesterolemia (FH) lack a normally functioning LDL receptor in both nonhepatic and hepatic tissues. 219 The ability of 125 l-apo A-l HDL to bind to FH hepatic membranes was evaluated (Table 4) . At saturation, these hepatic membranes demonstrated a significant reduction in the number of expressed LDL re- From 86 to 122 ng of hepatic membrane protein from normal and familial hypercholesterolemia individuals were incubated for 2 hours at 37° C with 350 ng 125 l-apo A-l HDL/ml in the absence (total binding) or presence (nonspecific binding) of tenfold excess unlabeled HDL. Specific binding is the difference between total and nonspecific binding. Values for normal membranes represent the means ± SE. ceptors. 19 However, both the total and specific binding of 125 l-apo A-l HDL to these membranes were normal or slightly increased. This indicates that the hepatic HDL receptor is genetically distinct from the LDL receptor in humans.
Finally, we assessed the regulation of hepatocyte HDL binding in vitro using the well differentiated human hepatoma cell line, HEPG2. HEPG2 saturably bound 125 l-apo A-l HDL after cholesterol preincubation ( Figure 5 ). The enhanced HDL binding with cholesterol preincubation contrasted with the 26% decline in 125 I-LDL binding and internalization observed in these cells under identical conditions. Furthermore, this upregulation of HDL binding is also present in normal human hepatocytes after cholesterol exposure for 24 hours (data not shown). Therefore the HEPG2 reflect normal human hepatocyte regulation of HDL binding.
As was noted with the hepatic membranes, the upregulated binding of HDL by HEPG2 was specific ( Figure 6 ). Neither LDL nor acetoacetylated LDL competed for HDL binding. In contrast, at 5 /xg unlabeled HDL protein/ml, only 50% of the 5 HEPG2 were plated in 2 cm 2 wells on Day 1 in medium containing 10% fetal calf serum. After 48 hours, the medium was changed. The preconfluent HEPG2 were incubated with either serum-free medium (o) or a serum-free medium containing 50 ^.g cholesterol/ml (•) for 24 hours. The specific binding is defined as the difference in binding observed in the absence and presence of tenfold excess unlabeled HDL after a 2-hour, 37° C incubation. Values represent the mean ± SE of triplicate samples.
Discussion
The apolipoproteins serve numerous physiologic functions in lipoprotein metabolism. In addition to the physical solubilization of lipid into aqueous media, apolipoproteins serve as enzyme cofactors and as recognition ligands for specific cellular receptors.
43
Apo B-containing lipoproteins have received the most attention as the ligand in cellular receptor-lipoprotein interactions. The specific receptor for apo B-containing lipoproteins is calcium-dependent, protease-sensitive, saturable, upregulated in cholesterol-depleted cells in vitro, and sensitive to arginine and lysine residues. 2 -3738 The putative role of LDL and its receptor pathway is to deliver cholesterol to tissues.
Physiologic roles independent of a solubilization function have been sought for apo A-l and apo A-ll, the principle apolipoprotein of HDL. The initial in vitro tissue culture studies did not suggest a receptorrecognition role for apo A-l or apo A-ll. 6 n - 46 The enhanced binding was correlated with enhanced cholesterol efflux mediated by HDL.
11
- 12 Therefore, binding of HDL by nonhepatic, nonsteroidogenic tissues, which appears to be mediated by apolipoproteins, has supported the concept of the delivery of cholesterol from peripheral cells to the liver. 5 The reverse cholesterol transport concept assumes that HDL cholesterol can be delivered to the liver. Partial hepatectomy 49 and metabolic turnover studies 50 -51 in the rat indicate that HDL cholesterol is efficiently delivered to the liver without concommitant degradation through lysosomal hydrolysis of the entire HDL particle. Utilizing metabolic turnover techniques and multicompartmental analysis, Schwartz and co-workers have demonstrated that both cholesteryl ester 52 and free cholesterol 53 in HDL are preferential sources of biliary cholesterol in man. Therefore, a receptor for HDL in liver membranes could facilitate the delivery of HDL cholesterol through a pathway independent of the LDL lysosomal delivery pathway.
We have demonstrated in the present study that the binding of HDL to human hepatic membranes is saturable and specific and does not depend upon the presence of apo E. Furthermore, binding is distinct from that reported previously for plasma lipoproteins in other mammalian species. Unlike LDL binding to human liver, HDL binding is EDTA-resistant 18 and the affinity of HDL binding is affected by temperature. The calcium-independent nature of HDL binding to human liver has also been reported previously in swine 27 and rabbits. 28 However, unlike previous evaluations of HDL binding to liver, the present study indicates a unique specificity of HDL binding to human membranes. Studies using either hepatocyte cultures or hepatic membranes have previously demonstrated some degree of competition of HDL, binding by other density classes of lipoprotein. 27 ffl ' "• x - 5 7 Whether expressed as /ng/ml or normalized to a molar concentration, asialofetuin and anti-apo B did not decrease LDL binding of 125 l-apo A-l HDL to hepatic membranes ( Figure 4 , Table 3 ). In addition, the HDL binding to human hepatic membranes was not affected by arginine and lysine residue modification, which impair apo B and apo E binding. 3738 However, nitration, which reportedly modifies tyrosine residues and decreases HDL metabolism by nonhepatic tissues, 5859 and anti-apo A-l and anti-apo A-ll attenuated HDL binding. These studies were performed by using HDL isolated from a patient with no circulating apo E. 29 As a result, the HDL binding observed in these studies can not be mediated by an apo E interaction with the hepatic apo E or apo B, E receptor. Although the chemical characteristics of the HDL membrane binding site are yet to be defined, the saturability and specificity demonstrated in the present studies are characteristic of receptors. Most well-characterized receptors are protein, but recently glycolipids have not only elicited transmembrane signals 54 but have also induced adsorptive endocytosis. 55 Further evaluation of the chemical nature of the hepatic HDL receptor is warranted. Therefore, binding of HDL to human hepatic membranes characterized by these membrane studies indicates that a receptor for HDL apolipoproteins that is distinct from any previously described hepatic lipoprotein receptor is present in human liver.
The study of isolated cellular membrane fractions allows for the rapid separation of bound and free ligand which is necessary for accurate determination of receptor number and affinity. Intact cell studies require sequential washes that disrupt the equilibrium between bound and free ligand. 60 This loss of equilibrium results in an overestimation in the affinity of binding. Although cell membrane binding studies lead to useful estimates of binding kinetics, intact cells are necessary for the study of receptor regulation. The current investigation indicated that HDL binding can be regulated. HEPG2, a well-differentiated human hepatoma cell line, modulated the binding of apo E-free HDL. As was observed in nonhepatic cells in vitro," preincubation of both HEPG2 and normal hepatocytes with cholesterol-enriched medium led to enhanced HDL binding by these cells. Although an upregulation of HDL binding by hepatocytes with cholesterol depletion (rather than cholesterol loading) would be more attractive for a reverse cholesterol transport role for this HDL receptor, such a scheme may be too simplistic. In contrast to nonhepatic tissues, which have only a few pathways by which cholesterol is metabolized, the hepatocyte can secrete cholesterol directly into bile, can convert cholesterol to bile acids, and can package cholesterol into lipoproteins during lipoprotein synthesis. Therefore, understanding the effect of cholesterol enrichment of the entire cell as well as the subcellular cholesterol compartments and understanding the metabolic fate of subcellular cholesterol pools are necessary to assess the role a receptor for HDL in liver would have in reverse cholesterol transport.
Finally, this hepatic HDL receptor appears to be genetically distinct from the hepatic LDL (apo B, E) receptor. The hepatic membranes from an LDL receptor-negative familial hypercholesterolemic homozygote also demonstrated defective hepatic LDL receptors. 19 However, these membranes bound apo E-free HDL normally (Table 4) . Therefore, in addition to the unique specificity and amino acid requirements, the binding of HDL appears to be genetically distinct from the hepatic LDL receptor system. These combined data indicate that human hepatic membranes manifest a unique and genetically distinct receptor for HDL that can be regulated in vitro.
